U.S., July 15 -- ClinicalTrials.gov registry received information related to the study (NCT07063199) titled 'Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP)' on July 03.
Brief Summary: To evaluate the safety and efficacy of Anti-CD38 Antibody in the treatment of elderly patients with primary immune thrombocytopenia in patients who have failed multiple treatment.
Study Start Date: Aug., 2025
Study Type: INTERVENTIONAL
Condition:
Immune Thrombocytopenia
Treatment
Intervention:
DRUG: Daratumumab Injection
This study adopts a prospective, single arm, open design method. Thirty subjects were enrolled in the study and were treated with CD38 monoclonal antibody (Daratumumab 16mg/kg/w) for 4 weeks.
T...